We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nondepleting Antibody Therapy Reverses Diabetes Symptoms in Mouse Model

By LabMedica International staff writers
Posted on 16 Jul 2012
A mouse diabetes model was treated by an immunotherapeutic approach based on novel nondepleting antibodies specific for the T-cell receptors CD4 and CD8.

Residual beta cells found at the time of the clinical onset of type I diabetes are sufficient to control hyperglycemia, if they can be rescued from ongoing autoimmune destruction. More...
To achieve this end, investigators at the University of North Carolina (Chapel Hill, NC, USA) developed an immunotherapeutic approach based on antibodies specific for the CD4 and CD8 receptors found on "autoreactive" T-cells. They then used these antibodies to treat members of a population of the mouse NOD diabetes model.

They reported in the June 29, 2012, online edition of the journal Diabetes that a short course of treatment with nondepleting antibodies specific for the CD4 and CD8 coreceptors rapidly reversed clinical disease in recent-onset diabetic NOD mice. Blood sugar levels returned to normal within 48 hours of treatment. Within five days, about 80% percent of the treated animals had entered diabetes remission with reversal of clinical symptoms.

Once established, remission was maintained indefinitely while immunity to foreign antigens was unimpaired. Induction of remission involved selective T-cell purging of the pancreas and draining pancreatic lymph nodes and upregulation of transforming growth factor (TGF)-beta1 by pancreas-resident antigen-presenting cells. Neutralization of TGF-beta1 blocked the induction of the remission process. In contrast, maintenance of remission was associated with tissue-specific immunoregulatory T cells.

"The protective effect is very rapid, and once established, is long-term," said senior author Dr. Roland Tisch, professor of microbiology and immunology at the University of North Carolina. "We followed the animals in excess of 400 days after the two antibody treatments, and the majority remained free of diabetes. And although the antibodies are cleared from within the animals in two to three weeks after treatment, the protective effect persists."

"We have demonstrated that the use of nondepleting antibodies is very robust," said Dr. Tisch. "We are now generating and plan to test antibodies that are specific for the human version of the CD4 and CD8 molecules."

Related Links:

University of North Carolina School



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.